What’s Next for Nektar Therapeutics?

What’s Next for Nektar Therapeutics?

Nektar Therapeutics (NASDAQ: NKTR) has a lot on its plate. The company's advancing its lead drug candidate, NKTR-181, to the FDA for use in chronic pain and its pipeline crisscrosses immuno-oncology and immunology. Shares of Nektar Therapeutics have been on a roll lately, but can its winning streak continue rewarding investors?

In this clip from The Motley Fool's Industry Focus: Healthcare, analyst Kristine Harjes and Todd Campbell explain why investors are flocking to include this biotech stock in portfolios.

A full transcript follows the video.

Continue reading

Source: Fool.com